Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Fourteen public and private parties, including pharmaceutical companies Astellas (TYO: 4503) and Merck KGaA (MRK: DE), have developed a drug for a 'forgotten' tropical disease: schistosomiasis. This ...